Liver Spatial Transcriptomics in Functional Zonation: Advances and Clinical Implications

Abstract

Spatial transcriptomics has revolutionized our understanding of liver functional zonation, providing unprecedented insights into the spatial organization of gene expression and its implications for hepatic physiology and pathology. This review synthesizes recent advances in spatial transcriptomic technologies and their application to deciphering liver zonation, discusses the clinical significance of spatially resolved molecular data, and explores emerging diagnostic and therapeutic opportunities. We highlight mechanistic underpinnings, clinical relevance, and translational potential, offering a comprehensive resource for clinicians and researchers.

Introduction

The concept of liver zonation, where distinct metabolic and functional domains exist within the hepatic lobule, has long been recognized as fundamental to understanding hepatic physiology and disease. Recent advances in spatial transcriptomics integrating high-throughput gene expression profiling with spatial localization have enabled the delineation of complex molecular patterns underlying zonation. These technologies provide insights into how spatial gene expression heterogeneity orchestrates liver function, influences disease progression, and informs targeted therapeutic strategies. As the field evolves, the integration of spatial transcriptomics into clinical and research paradigms is poised to transform hepatology.

Epidemiology / Disease Burden

Globally, liver diseases such as non-alcoholic fatty liver disease (NAFLD), viral hepatitis, and cirrhosis represent significant health burdens, with millions affected and substantial morbidity and mortality. A nuanced understanding of liver zonation contributes to elucidating regional susceptibilities within the hepatic parenchyma. Diseases often localize or progress preferentially within specific zones such as centrilobular injury in drug-induced liver injury or periportal fibrosis in chronic hepatitis. The ability to spatially resolve gene expression profiles enhances our ability to map and quantify this zonal vulnerability, offering new perspectives for epidemiological stratification and targeted interventions.

Pathophysiology

The hepatic lobule is organized into zones from periportal (zone 1) to pericentral (zone 3) each characterized by unique metabolic activities governed by gradients of oxygen, nutrients, and signaling molecules. Spatial transcriptomics has revealed zone-specific expression of genes involved in gluconeogenesis, detoxification, bile acid synthesis, and xenobiotic metabolism. Disruption of these gradients, as seen in hypoxia, steatosis, or fibrosis, leads to altered zonal gene expression and contributes to pathogenesis. Mechanistically, Wnt/β-catenin signaling, oxygen tension, and hormonal cues coordinate zonal gene expression, with spatial transcriptomic studies further uncovering previously unrecognized regulatory networks and cell-type specific contributions, including those of hepatocytes, Kupffer cells, and hepatic stellate cells.

Risk Factors

Genetic predispositions, metabolic syndrome, viral infections, toxic exposures, and chronic inflammation are well-established risk factors for hepatic dysfunction. Recent spatial transcriptomics studies suggest that risk factors may exert zone-specific effects at the molecular level, influencing cellular susceptibility to injury and regeneration. For instance, the preferential accumulation of lipids in zone 3 hepatocytes in NAFLD or the spatially restricted activation of fibrogenic pathways in response to chronic insults underscore the importance of considering zonal context in risk assessment and intervention.

Clinical Features

Clinical manifestations of liver diseases often reflect underlying zonal pathology. Centrilobular necrosis, periportal inflammation, or midzonal steatosis can be directly correlated with spatially resolved transcriptomic patterns. Emerging evidence indicates that spatial transcriptomic signatures may serve as biomarkers for specific disease subtypes, aiding in differential diagnosis and prognostication. For clinicians, recognizing the zonal basis of histopathological features can refine diagnostic accuracy and inform tailored management strategies.

Diagnosis

Traditional diagnostic modalities including histopathology and serum biomarkers offer limited spatial resolution. Spatial transcriptomics supplements these approaches by providing high-fidelity maps of gene expression within the hepatic lobule. By integrating spatial transcriptomic data with histological and imaging findings, clinicians can achieve more precise localization of pathology, differentiate between disease etiologies, and identify early molecular changes preceding overt morphological alterations. This approach heralds a new era of precision diagnostics in hepatology.

Treatment & Management

Understanding the spatial heterogeneity of gene expression informs targeted therapeutic strategies. Zone-specific delivery of interventions such as antioxidants to pericentral regions vulnerable to oxidative stress, or modulation of periportal metabolic pathways can enhance efficacy and limit off-target effects. Spatial transcriptomic insights also guide the development of novel drugs targeting zone-restricted molecular pathways, offering promising avenues for personalized medicine in liver diseases.

Recent Advances / Emerging Therapies

Recent advances in spatial transcriptomic technologies, including Slide-seq, Visium, and MERFISH, enable high-resolution mapping of gene expression in situ. These platforms have facilitated the discovery of previously unappreciated zonal regulators and intercellular communication networks. Emerging therapies leverage these insights, with experimental interventions targeting zone-specific pathways in models of fibrosis, steatohepatitis, and hepatocellular carcinoma. Integration with single-cell sequencing and spatial proteomics further enhances the granularity of data, supporting the development of multi-modal diagnostic and therapeutic modalities.

Guideline Recommendations

While official clinical guidelines have yet to fully incorporate spatial transcriptomics, leading hepatology societies increasingly recognize the value of spatially resolved molecular data. Best practices recommend the integration of spatial transcriptomic findings into research protocols, biomarker discovery, and clinical trial design. As evidence accumulates, future guidelines are expected to endorse the use of spatial transcriptomics for disease stratification, risk assessment, and tailored therapeutic interventions in clinical hepatology.

Conclusion

Spatial transcriptomics is redefining our understanding of liver functional zonation, offering transformative insights into hepatic biology, disease mechanisms, and clinical management. By elucidating the spatial context of gene expression, this technology bridges the gap between molecular biology and histopathology, enabling precision diagnostics and targeted therapy. Ongoing research and integration into clinical practice promise to unlock new frontiers in hepatology, ultimately improving outcomes for patients with liver disease.